Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 9/2016

01-09-2016 | Inflammatory Bowel Disease (S Hanauer, Section Editor)

Next-Generation Therapeutics for Inflammatory Bowel Disease

Authors: Parambir S. Dulai, William J. Sandborn

Published in: Current Gastroenterology Reports | Issue 9/2016

Login to get access

Abstract

Tumor necrosis factor (TNF) antagonists are the cornerstone of therapy for moderately to severely active inflammatory bowel disease (IBD). Although our understanding of pharmacokinetics, pharmacodynamics, and treatment optimization for these agents has evolved considerably over the past decade, a substantial majority of individuals fail to respond or lose response to TNF-antagonists over time. A need therefore remains for efficacious treatment options in these patients. Alternative immunological targets have now been identified, and several novel therapeutic agents are in development for IBD. In this review article, we discuss these novel therapeutic agents, with a particular focus on those demonstrated to be efficacious in phase 2 and 3 clinical trials. We further discuss considerations to be made when integrating these agents into routine practice over the next decade.
Literature
1.
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet (Lond Engl). 2008;371(9613):660–7.CrossRef
2.
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet (Lond Engl). 2015;386(10006):1825–34.CrossRef
3.
Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014;63(12):1843–53.CrossRefPubMed
4.
Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–9.e3.CrossRefPubMed
5.
Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015;82(2):246–55.CrossRefPubMed
6.
Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease—algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51.CrossRefPubMed
7.
Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12(9):1443–51. quiz e88-9.CrossRefPubMed
8.
Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43(3):525–41.CrossRefPubMed
9.•
Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754–62. Pivotal phase 2 trial of a first in class biologic agent that modulates sphingosine-1-phospate receptors and inhibits T cell release from lymph nodes.CrossRefPubMed
10.•
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. Phase 3 trial that led to the approval of vedolizumab in ulcerative colitis.CrossRefPubMed
11.•
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21. Phase 3 trial that led to the approval of vedolizumab in Crohn's disease.CrossRefPubMed
12.
Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice—a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43(10):1090–102.CrossRefPubMed
13.
Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2016.
14.
Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, et al. Vedolizumab effectiveness and safety over the first year of use in an ibd clinical practice. J Crohns Colitis. 2016;10(4):402–9.CrossRefPubMed
15.
Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21(12):2879–85.CrossRefPubMed
16.
Peerani F, Narula N, Dulai PS, Chaudrey K, Whitehead D, Hudesman D, et al. Sa1888 Efficacy and predictors of outcomes of vedolizumab for ulcerative colitis in clinical practice. Gastroenterology.150(4):S392-S3.
17.
Dulai PS, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, et al. Sa1889 Efficacy and predictors of outcomes of vedolizumab for Crohn’s disease in clinical practice. Gastroenterology.150(4):S393.
18.•
Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–27.e3. This study demonstrated that rates of clinical remission in Crohn’s disease with vedolizumab were significantly influenced by the duration of therapy, and this more pronounced among individuals with prior exposure to anti-TNF therapy. CrossRefPubMed
19.
Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet (Lond Engl). 2014;384(9940):309–18.CrossRef
20.
Reinisch W, Sandborn W, Danese S, Cataldi F, Hebuterne X, Salzberg B, et al. 901a A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis: results of the TURANDOT Study. Gastroenterology.148(4):S-1193.
21.
Sandborn W, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, et al. 825 Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease: results of the OPERA study. Gastroenterology.148(4):S-162.
22.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–28.CrossRefPubMed
23.
Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao L-L, et al. O-001 a multicenter, double-blind, placebo-controlled phase3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn’s disease refractory to Anti-TFN[alpha]: UNITI-1. Inflamm Bowel Dis. 2016;22:S1.CrossRefPubMed
24.
Late-breaking abstracts. United European Gastroenterology Journal. 2015;3(6):561-71.
25.
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc. 2016;14(2):242–50. e1-2.CrossRef
26.
Kopylov U, Afif W, Cohen A, Bitton A, Wild G, Bessissow T, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—the McGill experience. J Crohns colitis. 2014;8(11):1516–22.CrossRefPubMed
27.
Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108(4):601–9.CrossRefPubMedPubMedCentral
28.•
Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372(12):1104–13. Pivotal phase 2 trial of a first in class biologic anti-sense agent.CrossRefPubMed
29.
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–24.CrossRefPubMed
30.
OP019. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials. J Crohn's Colitis. 2016;10 suppl 1:S15–S.
31.
DOP071. Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of phase 3 induction studies. J Crohn's Colitis. 2016;10 suppl 1:S73–4.CrossRef
32.
OP028. Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 studies. J Crohn's Colitis. 2016;10 suppl 1:S23–4.CrossRef
33.
Osterman MT, Roblin X, Glover SC, Navaneethan U, Popa MA, Wyant T, et al. 512 Association of vedolizumab drug concentrations at or before week 6 with remission at week 14 in moderately to severely active ulcerative colitis patients from GEMINI 1. Gastroenterology.150(4):S105.
34.
Hirten R, Longman RS, Bosworth BP, Steinlauf A, Scherl E. Vedolizumab and infliximab combination therapy in the treatment of Crohn’s disease. Am J Gastroenterol. 2015;110(12):1737–8.CrossRefPubMed
Metadata
Title
Next-Generation Therapeutics for Inflammatory Bowel Disease
Authors
Parambir S. Dulai
William J. Sandborn
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 9/2016
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-016-0522-0

Other articles of this Issue 9/2016

Current Gastroenterology Reports 9/2016 Go to the issue

Nutrition and Obesity (S McClave and J Obert, Section Editors)

The Critical Care Obesity Paradox and Implications for Nutrition Support

Large Intestine (B Cash, Section Editor)

Progress in Our Understanding of the Gut Microbiome: Implications for the Clinician

Nutrition and Obesity (S McClave, Section Editor)

Intestinal Failure: New Definition and Clinical Implications

Stomach and Duodenum (J Pisegna and J Benhammou, Section Editors)

Laparoscopic-Assisted Percutaneous Endoscopic Gastrostomy

Inflammatory Bowel Disease (S Hanauer, Section Editor)

Approach to the Patient with Mild Crohn’s Disease: a 2016 Update

Esophagus (JO Clarke and NK Ahuja, Section Editors)

Endoscopic Options for Gastroesophageal Reflux: Where Are We Now and What Does the Future Hold?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits